Fresh analysis reveals that people who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who halt traditional diet and exercise regimens.
Published data in a major medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users buying these drugs must be aware of the potential of quick rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about 18 months.
Weighing Treatments
The study, which examined dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with older methods.
Scientists note that individuals who lose weight through diet and exercise typically have a slower weight regain—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists propose the mode of action of the drugs is key to understanding the heightened rebound.
The injections copy a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, given the significant potential of relapse, the treatment is often long-term.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the long-term character of excess weight," comparing it to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs describe a intense resurgence of hunger.
"It was like a trigger activating and I was suddenly extremely hungry," described one woman.
This difficulty is worsened if individuals have not developed sustainable dietary or behavioural modifications during therapy.
Growing Use
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are powerful tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural changes.
